KARPAS 231
06120601, human blood (leukemia), Single round to polymorphic cells growing in suspension
Synonym(s):
KARPAS, 231
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
product name
KARPAS 231, 06120601, from human blood(leukemia)
biological source
human blood (leukemia)
growth mode
Suspension
karyotype
Not specified
morphology
Single round to polymorphic cells growing in suspension
products
Not specified
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
Cell Line Origin
Human B-cell leukemia
Cell Line Description
Established from peripheral blood of a 71 year-old woman at diagnosis of B-cell acute lymphoblastic leukemia (ALL). No rearrangement of C-MYC DNA sequences.
DNA Profile
Not specified
Culture Medium
RPMI 1640 + 2 mM Glutamine + 10% Fetal Bovine Serum (FBS).
Subculture Routine
Maintain cultures between 0.5 - 2 x1000,000 cells/ml; 5% CO2; 37 °C. Doubling time approximately 60 hours. Split saturated culture 1:2 every 2-4 days. Cells are single round to polymorphic and grow in suspension.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Disclaimer
This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service